menu
    • menu
    [{"orgOrder":0,"company":"VectivBio","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"Apraglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"","sponsorNew":"VectivBio \/ Surveyor Capital","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Surveyor Capital"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Comet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"VB-1197","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ VectivBio Holding","highestDevelopmentStatusID":"4","companyTruncated":"VectivBio \/ VectivBio Holding"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ SVB Securities"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Jefferies"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Apraglutide","moa":"GLP-2 receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Not Applicable"},{"orgOrder":0,"company":"VectivBio","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Apraglutide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"VectivBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"8","companyTruncated":"VectivBio \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":1,"dosageForm":"Injectable\/Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"VectivBio","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Apraglutide","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"VectivBio","amount2":1,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":1,"dosageForm":"Injection","sponsorNew":"VectivBio \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"VectivBio \/ Ironwood Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by VectivBio

    Menu

    VectivBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ironwood Announces the Completion of Squeeze-Out Merger with VectivBio

                            Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : $1,000.0 million

                            December 12, 2023

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering No...

                            Details : Through the acquisition, Ironwood expands its portfolio with the addition of FE203799 (apraglutide), a next-generation, GLP-2 analog in Phase 3 for short bowel syndrome with intestinal failure (SBS-IF).

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : $1,000.0 million

                            May 22, 2023

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Ironwood Pharmaceuticals

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan

                            Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 13, 2023

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Stu...

                            Details : FE203799 (apraglutide) is an investigational new drug that is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology.

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

                            Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 18, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares

                            Details : VectivBio intends to use the net proceeds from the offering, (i) clinical development and pre-commercialization activities for its lead product FE203799 (apraglutide) and (ii) general corporate purposes, including general and administrative expenses and ...

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 13, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Jefferies

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apragluti...

                            Details : Apraglutide is investigational new drug that is next-generation, long-acting synthetic GLP-2 analog being developed for range of rare gastrointestinal diseases.

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 13, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : SVB Securities

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

                            Details : VectivBio intends to use the net proceeds, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund clinical development and pre-commercialization activities for its lead product candidate FE203799 (Apragl...

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            June 15, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : SVB Securities

                            Deal Size : $30.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acu...

                            Details : FE203799 (apraglutide) is a next-generation, synthetic GLP-2 analog rationally designed with the potential to offer an improved safety and efficacy profile relative to other agents in its class and less frequent dosing.

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed

                            VectivBio

                            Switzerland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the C...

                            Details : The company entered into agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-hos...

                            Brand Name : FE203799

                            Molecule Type : Peptide

                            Upfront Cash : $30.0 million

                            March 30, 2022

                            Lead Product(s) : Apraglutide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Asahi Kasei Pharma

                            Deal Size : $200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth